Dying on a Payment Plan: How Big Pharma Turned Your Insulin Into a Subscription Service

Let's start with a number: $1. That's approximately what it costs to manufacture a vial of insulin. Now here's another number: $300. That's roughly what an American diabetic without adequate insurance pays for that same vial at a pharmacy counter in 2024. Somewhere between those two figures lives one of the most breathtaking corporate heists in modern history — and unlike most heists, this one requires the victim to keep showing up, wallet in hand, or die.

Some 37 million Americans have diabetes. Of those, roughly 8 million depend on insulin to stay alive. Not to feel better. Not to perform at peak optimization. To stay alive. That distinction matters, because pharmaceutical companies discovered decades ago that when you sell something people cannot live without, you've found the rarest of economic unicorns: a customer who literally cannot say no.

The Patent Carousel That Never Stops Spinning

Here's the part the pharmaceutical industry really doesn't want you thinking too hard about: insulin itself is not patentable. The original discovery by Frederick Banting and Charles Best was deliberately not patented in 1923, specifically so it would be affordable and accessible. Banting sold the patent to the University of Toronto for $1 because he believed no one should profit from a discovery that saves lives.

Pharmaceutical executives apparently did not get that memo.

What companies like Eli Lilly, Novo Nordisk, and Sanofi figured out is that while you can't patent insulin, you absolutely can patent the delivery device. The formulation. The concentration. The pen. The cap on the pen. The slightly tweaked molecular structure that functions identically to the old version but now carries a shiny new patent and a fresh 20-year monopoly window. This practice has a name in policy circles: evergreening. In plain English, it means manufacturing reasons to never let a drug go generic.

Between 2001 and 2019, Eli Lilly filed over 50 patents related to insulin products. Not 50 revolutionary breakthroughs. Fifty legal maneuvers designed to ensure that the clock on generic competition never quite runs out. Think of it less like pharmaceutical innovation and more like a law firm billing you for rearranging the furniture in a house they've already sold you three times.

The Rebate Maze Nobody Asked For

If you've ever tried to understand why your insulin costs what it costs, congratulations — you've stumbled into a financial structure so deliberately convoluted that even pharmacists sometimes can't explain it. The pricing chain involves manufacturers, pharmacy benefit managers (PBMs), insurers, and pharmacies, each taking a cut, each negotiating secret rebates, and none of them particularly motivated to make the final number smaller for the person actually holding the prescription.

PBMs — companies like Express Scripts, CVS Caremark, and OptumRx — negotiate rebates from drug manufacturers in exchange for favorable formulary placement. In theory, these savings pass to consumers. In practice, they mostly don't. What the system does accomplish is creating a perverse incentive to keep list prices artificially high, because bigger list prices mean bigger rebates to negotiate over. The patient at the pharmacy counter, meanwhile, often pays a copay calculated as a percentage of that bloated list price.

It's a Rube Goldberg machine built to extract maximum revenue while providing everyone in the chain with plausible deniability about who, exactly, is responsible for the number on the receipt.

Rationing Insulin in the Richest Country on Earth

The consequences of this system are not abstract policy outcomes. They are people dying in parking lots.

Alec Smith was 26 years old when he aged off his parents' insurance. He was working a restaurant job that didn't offer coverage. He began rationing his insulin — stretching doses, skipping injections, doing the math that no one should ever have to do between rent and survival. He died of diabetic ketoacidosis in June 2017, one month after his birthday, $1,200 short of the insulin he needed.

His story is not unique. It is, horrifyingly, a category. Researchers at Yale found that one in four insulin-dependent diabetics in the United States reports rationing insulin due to cost. One in four. In a country that spends more on healthcare per capita than any nation on earth, a quarter of people dependent on a century-old medication are gambling with their lives because the pricing structure demands it.

And when these stories surface, when the public outrage reaches a sufficient boil, what does the industry do? It announces voluntary price caps. Eli Lilly capped its insulin at $35 a month in 2023 — a move celebrated in press releases as an act of corporate generosity. What went unmentioned is that $35 is still roughly 35 times the cost of production, and the cap only applies to those who can navigate the right insurance pathways. The uninsured, the underinsured, the people most likely to be rationing in the first place? The fine print varies.

The Regulatory Revolving Door Keeps Spinning

None of this would be possible without a regulatory environment that has been carefully tended by the industry it's supposed to oversee. The FDA's patent approval process, the Hatch-Waxman Act's provisions that allow brand manufacturers to delay generic competition, the lobbying expenditures that reliably dwarf those of any consumer group — these are the structural foundations on which the insulin pricing system rests.

The pharmaceutical industry spent over $370 million lobbying Congress in 2022 alone. For context, that's more than the oil and gas and defense industries combined. When senators propose legislation to allow Medicare to negotiate drug prices, it somehow takes decades to pass in watered-down form. When drug companies propose another round of evergreening patents, the pipeline moves with remarkable efficiency.

The Inflation Reduction Act of 2022 did grant Medicare the ability to negotiate prices on a limited set of drugs — a genuine, if modest, step forward. But the structural machinery of patent manipulation, PBM opacity, and regulatory capture remains largely intact. A $35 cap is not a solution to a system designed to price people into desperation. It's a pressure valve.

What a Real Market Would Look Like

Here is the thing about insulin that should make everyone furious: we know what it costs in other countries. In Canada, a vial of insulin averages around $12. In Germany, roughly $11. In Australia, even less. These aren't charity programs. These are functioning markets with actual regulatory frameworks that prevent a life-saving drug from being priced like a luxury good.

American diabetics have literally driven to Canada to buy insulin. They've organized cross-border caravans. They've done the math and concluded that a road trip is cheaper than their local pharmacy. This is not a free market functioning as intended. This is a captive market functioning exactly as intended — by the people who designed it.

Banting gave away his discovery because he believed human life was worth more than a patent portfolio. A hundred years later, three companies have decided that human life is worth precisely as much as the market will bear before the customer dies trying to afford it.

That's not innovation. That's a business model built on a body count.